Keymed Biosciences, Inc.
HHKEX:216279.10
HKD
-7.05
(-8.18%)
ISIN
KYG5252B1023
CUSIP
G5252B102
Return %
Stock
S&P 500
1Y
26.97
14.20
3Y
49.95
81.12
5Y
92.22
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Bo Chen
- Full Time Employees
- 1,625
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 669 Fenghuang Road Chengdu SI China 610219
- IPO Date
- Jul 8, 2021
- Website
- keymedbio.com
- Similar Companies
- Business
- Keymed Biosciences Inc. (2162.HK) is a biotechnology company focused on the discovery, development, and commercialization of innovative biological therapies targeting autoimmune diseases, oncology, and chronic conditions; its core pipeline encompasses over 30 Class I novel drug programs, including monoclonal antibodies such as Stapokibart (CM310, IL-4Rα mAb, approved by China's NMPA for moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis), CM313 (CD38 mAb for immune thrombocytopenia, systemic lupus erythematosus, and IgA nephropathy), CM326 (TSLP mAb), and CM383 (Aβ protofibrils mAb for Alzheimer's disease), bispecific antibodies like CM512 (TSLPxIL-13), CM355 (CD20xCD3), CM336 (BCMAxCD3), CM350 (GPC3xCD3), CM380 (GPRC5DxCD3), and CM369 (CCR8 mAb), as well as antibody-drug conjugates including CMG901 (Claudin 18.2 ADC, partnered with AstraZeneca and granted FDA Orphan Drug and Fast Track Designations) and CM518D1 (CDH17 ADC); the company operates a fully integrated platform from antibody discovery to commercial manufacturing with cGMP-compliant facilities supporting 20,000 liters of capacity. Founded in 2016 and headquartered in Chengdu, China, with additional sites in Beijing, Shanghai, Wuhan, Nanjing, Guangzhou, and Jinan, Keymed employs over 1,300 staff and primarily serves markets in Greater China while pursuing global expansion through diversified business development. Recent developments include NMPA approvals for Stapokibart's three indications in 2024-2025 generating initial sales revenue, Phase III initiations for adolescent atopic dermatitis and nodular prurigo, positive clinical data presentations at ASCO, EAACI, ASH, and publications in The Lancet Oncology and New England Journal of Medicine; strategic out-licensing deals such as July 2024 agreement with Belenos Biosciences for CM512 and CM536 (US$15 million upfront, up to US$170 million milestones, 30% equity), November 2024 pact with Platina Medicines for CM336 (US$16 million upfront, up to US$610 million milestones), January 2025 exclusive license to Timberlyne Therapeutics for CM313 (US$30 million upfront, up to US$337.5 million milestones, largest shareholder position), and January 2025 collaboration with Prolium via InnoCare JV for CM355 in non-oncology and ex-Asia oncology indications; 2024 revenue reached RMB 430 million (21% YoY growth) driven by licensing and Stapokibart sales, with RMB 2.1 billion cash reserves supporting ongoing R&D expenditure of RMB 730 million.